riluzole has been researched along with Cognitive Dysfunction in 2 studies
Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.
Cognitive Dysfunction: Diminished or impaired mental and/or intellectual function.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Here, we evaluate 2-Amino-6-(trifluoromethoxy) benzothiazole (riluzole) as an early intervention strategy for Alzheimer's disease (AD), aimed at restoring glutamate neurotransmission prior to substantial Beta amyloid (Aβ) plaque accumulation and cognitive decline." | 8.02 | Riluzole attenuates glutamatergic tone and cognitive decline in AβPP/PS1 mice. ( Bartke, A; Britz, J; Broderick, SO; Delfino, K; Esperant-Hilaire, N; Findley, CA; Hascup, ER; Hascup, KN; Tischkau, S, 2021) |
| "This Editorial highlights a remarkable study in the current issue of the Journal of Neurochemistry in which Hascup and coworkers provide novel data showing that riluzole, an anti-glutamatergic drug, may be a promising early intervention strategy for Alzheimer's disease (AD), aimed at restoring glutamate neurotransmission prior to amyloid beta (Aβ) plaque accumulation and cognitive decline." | 8.02 | Hippocampal hyperglutamatergic signaling matters: Early targeting glutamate neurotransmission as a preventive strategy in Alzheimer's disease: An Editorial Highlight for "Riluzole attenuates glutamatergic tone and cognitive decline in AβPP/PS1 mice" on pa ( Gulyaeva, NV, 2021) |
| " Here, we evaluate 2-Amino-6-(trifluoromethoxy) benzothiazole (riluzole) as an early intervention strategy for Alzheimer's disease (AD), aimed at restoring glutamate neurotransmission prior to substantial Beta amyloid (Aβ) plaque accumulation and cognitive decline." | 4.02 | Riluzole attenuates glutamatergic tone and cognitive decline in AβPP/PS1 mice. ( Bartke, A; Britz, J; Broderick, SO; Delfino, K; Esperant-Hilaire, N; Findley, CA; Hascup, ER; Hascup, KN; Tischkau, S, 2021) |
| "This Editorial highlights a remarkable study in the current issue of the Journal of Neurochemistry in which Hascup and coworkers provide novel data showing that riluzole, an anti-glutamatergic drug, may be a promising early intervention strategy for Alzheimer's disease (AD), aimed at restoring glutamate neurotransmission prior to amyloid beta (Aβ) plaque accumulation and cognitive decline." | 4.02 | Hippocampal hyperglutamatergic signaling matters: Early targeting glutamate neurotransmission as a preventive strategy in Alzheimer's disease: An Editorial Highlight for "Riluzole attenuates glutamatergic tone and cognitive decline in AβPP/PS1 mice" on pa ( Gulyaeva, NV, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hascup, KN | 1 |
| Findley, CA | 1 |
| Britz, J | 1 |
| Esperant-Hilaire, N | 1 |
| Broderick, SO | 1 |
| Delfino, K | 1 |
| Tischkau, S | 1 |
| Bartke, A | 1 |
| Hascup, ER | 1 |
| Gulyaeva, NV | 1 |
2 other studies available for riluzole and Cognitive Dysfunction
| Article | Year |
|---|---|
Riluzole attenuates glutamatergic tone and cognitive decline in AβPP/PS1 mice.
Topics: Amyloid beta-Protein Precursor; Animals; Cognitive Dysfunction; Glutamic Acid; Male; Maze Learning; | 2021 |
Hippocampal hyperglutamatergic signaling matters: Early targeting glutamate neurotransmission as a preventive strategy in Alzheimer's disease: An Editorial Highlight for "Riluzole attenuates glutamatergic tone and cognitive decline in AβPP/PS1 mice" on pa
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Cognitive Dysfunc | 2021 |